News
Obesity-focused biotech Kailera joins IPO queue in US
Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
R&D
Changing Faces: Board of Directors and Advisory Boards, Febr...
Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.
News
Otsuka grows in neuroplastogens with $1.225bn Transcend buy
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
News
Lilly puts up to $2.75bn into Insilico alliance
Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
R&D
Ending trial-and-error: How psychedelics and precision medic...
The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
